Listen to AC Forum board member hematologist Jori May, MD on how to successfully plan, fund, and implement an Anticoagulation Stewardship program (April 17, 2024).
Don’t miss our upcoming webinar on April 30, 2024 @ 12:00 PM ET!
Andexanet alfa is a specific reversal agent approved to reverse the anticoagulant effects of apixaban and rivaroxaban. The Annexa-I trial was stopped early by the DSMB due to better efficacy with andexanet alfa compared with standard of care treatments. This webinar will present key findings from this trial.
Presenters:
Jean Connors, MD (Moderator)
Jori May, MD (Moderator)
Ashkan Shoamanesh, MD (Presenter)
Deborah Siegal, MD, MSc, FRCPC (Panelist)
Jerrold Levy, MD, FAHA, FCCM (Panelist)
Securing administrative leadership support for Anticoagulation Stewardship programs is often a significant barrier to implementation. In a new resource in the Journal of American College of Clinical Pharmacy entitled "Securing Administrative Leadership Commitment for Anticoagulation Stewardship Programs," we present a structured approach to guide clinicians advocating to leadership for stewardship programs at their institutions. Elevate your understanding and become a catalyst for positive change in anticoagulation care!
Watch AC Forum President-Elect Geoff Barnes, MD, MSc, with Al Roker on 3rd Hour Today (October 27, 2023). Tune into a discussion about common risk factors, warning signs, and what to do in suspected cases of PE and DVT.
Curated & searchable literature database by topic, updated every two weeks.
View Literature Update
April 30, 2024 | 12:00 PM ET
Webinar: Update on Andexanet Alfa for Reversal of FXa Inhibitors: Annexa-I Trial Webinar
May 17-18, 2024
Bootcamp - Nashville
April 3-5, 2025
AC Forum National Conference in Washington, DC